Nephrogen
ActiveCurative genetic medicines for kidney diseases
About
Nephrogen is a Stanford biotech spin-out developing curative genetic medicines for kidney and pancreatic diseases. Kidney disease alone affects 1 in 7 Americans, and neither indication has any approved gene-based therapies. Nephrogen's underlying platform combines AI and high-throughput screening to engineer safer, more efficient, and less expensive gene delivery vehicles for reaching the kidney and pancreas, and has attracted non-dilutive funding from seven major pharmaceutical companies including Merck KGaA, Novartis, and Bristol Myers Squibb.
Founders
No founder data available for this company.
Related startups
AI platform accelerating therapies for rare & inflammatory diseases.
Bioengineered kidneys for patients with kidney failure
